These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 19051222

  • 1. Evolution of stimulants to treat ADHD: transdermal methylphenidate.
    Patrick KS, Straughn AB, Perkins JS, González MA.
    Hum Psychopharmacol; 2009 Jan; 24(1):1-17. PubMed ID: 19051222
    [Abstract] [Full Text] [Related]

  • 2. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
    Findling RL, Dinh S.
    CNS Drugs; 2014 Mar; 28(3):217-28. PubMed ID: 24532028
    [Abstract] [Full Text] [Related]

  • 3. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR, Scott LJ.
    Drugs; 2006 Mar; 66(8):1117-26. PubMed ID: 16789796
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study.
    Pierce D, Dixon CM, Wigal SB, McGough JJ.
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):355-64. PubMed ID: 18759645
    [Abstract] [Full Text] [Related]

  • 5. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations.
    Childress AC, Komolova M, Sallee FR.
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):937-974. PubMed ID: 31581854
    [Abstract] [Full Text] [Related]

  • 6. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group.
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [Abstract] [Full Text] [Related]

  • 7. Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations.
    Bell GH, Novak AJ, Griffin WC, Patrick KS.
    J Pharm Sci; 2011 Jul; 100(7):2966-78. PubMed ID: 21240977
    [Abstract] [Full Text] [Related]

  • 8. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS, Radke JL, Raymond JR, Koller L, Nguyen LV, Rodriguez W, Straughn AB.
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [Abstract] [Full Text] [Related]

  • 9. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
    González MA, Campbell D, Rubin J.
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
    [Abstract] [Full Text] [Related]

  • 10. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M, Mao AR, Doyle RL.
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [Abstract] [Full Text] [Related]

  • 12. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
    Warshaw EM, Paller AS, Fowler JF, Zirwas MJ.
    Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
    [Abstract] [Full Text] [Related]

  • 13. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A, Newcorn J, Stark JG, McMahen R, Tengler M, Sikes C.
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [Abstract] [Full Text] [Related]

  • 14. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH, Polcari A, Foley M, Valente E, McGreenery CE, Chang WW, McKay G, Midha KK.
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [Abstract] [Full Text] [Related]

  • 15. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D, Katic A, Buckwalter M, Webster K.
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [Abstract] [Full Text] [Related]

  • 16. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B.
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [Abstract] [Full Text] [Related]

  • 17. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG.
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [Abstract] [Full Text] [Related]

  • 18. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
    Heal DJ, Pierce DM.
    CNS Drugs; 2006 Jun; 20(9):713-38. PubMed ID: 16953648
    [Abstract] [Full Text] [Related]

  • 19. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D.
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [Abstract] [Full Text] [Related]

  • 20. Critical assessment of the methylphenidate transdermal system.
    Kowalik S, Minami H, Silva RR.
    Drugs Today (Barc); 2007 Aug; 43(8):515-27. PubMed ID: 17925883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.